Similar Papers

Paper Title
Journal
Date
Author
PEARLS: Is Our Use of Prostate-specific Membrane Antigen Positron Emission Tomography-Computed Tomography Meaningful for Our Patients?
J.R Murray ... E Hall
Clinical Oncology | VOL. 34
J.R Murray, et. al.J.R Murray ... E Hall
29 May 2022
Intravaginal brachytherapy alone for intermediate-risk endometrial cancer
Kaled M Alektiar ... Ennapadam Venkatraman
International Journal of Radiation Oncology*Biology*Physics | VOL. 62
Kaled M Alektiar, et. al.Kaled M Alektiar ... Ennapadam Venkatraman
10 Mar 2005
The Role of Race and Insurance Status on Prostate Cancer Risk-group at the Time of Presentation to a Southeastern North Carolina Private Radiation Oncology Practice
M.A Papagikos ... M.B Meyerson
International Journal of Radiation Oncology*Biology*Physics | VOL. 72
M.A Papagikos, et. al.M.A Papagikos ... M.B Meyerson
20 Aug 2008
PD63-01 RADICAL PROSTATECTOMY FOR PATIENTS WITH HIGH-RISK, VERY-HIGH RISK, OR METASTATIC PROSTATE CANCER: ONCOLOGIC RESULTS FROM THE MUSIC STATEWIDE COLLABORATIVE
Brian Lane* ... Arvin George
Journal of Urology | VOL. 203
Brian Lane*, et. al.Brian Lane* ... Arvin George
01 Apr 2020
View more papers

More From: International Journal of Radiation Oncology*Biology*Physics

Paper Title
Journal
Date
Author
Defining the optimal radiation-induced lymphopenia metric to discern its survival impact in esophageal cancer.
Pim J.J Damen ... Peter S.N Van Rossum
International Journal of Radiation Oncology*Biology*Physics | VOL. -
Pim J.J Damen, et. al.Pim J.J Damen ... Peter S.N Van Rossum
01 Jan 2025
Issue Highlights
-
International Journal of Radiation Oncology*Biology*Physics | VOL. -
--
01 Jan 2025
Combined molecular subclass and immune phenotype correlate to atezolizumab plus radiation therapy response in invasive bladder cancer: BPT-ART Phase II study
Yoshiyuki Nagumo ... Hiroyuki Nishiyama
International Journal of Radiation Oncology*Biology*Physics | VOL. -
Yoshiyuki Nagumo, et. al.Yoshiyuki Nagumo ... Hiroyuki Nishiyama
01 Jan 2025
Pelvic regional control with 25Gy in 5 fractions in SBRT for high risk prostate cancer: Pooled prospective outcomes from the SHARP consortium
Vedang Murthy ... Amar U Kishan
International Journal of Radiation Oncology*Biology*Physics | VOL. -
Vedang Murthy, et. al.Vedang Murthy ... Amar U Kishan
01 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.